Rivastigmine Bitartrate API

Name	Rivastigmine bitartrate
Chinese name	重酒石酸卡巴拉汀
Cas Number	129101-54-8
Source	India
Qualifications	/-/-/-/-

Rivastigmine bitartrate is the bitartrate of Alzheimer's disease treatment drug rivastigmine. It was first developed by Novartis, Switzerland. It was approved by the FDA on April 21, 2000. It is a carbamate brain choice choline. Esterase inhibitors. Rivastigmine bitartrate can simultaneously inhibit acetylcholinesterase and butyrylcholinesterase, and promote cholinergic nerve conduction by delaying the degradation of acetylcholine released by cholinergic neurons, which can improve cholinergic-mediated cognition Dysfunction, thereby improving the cognitive function of patients with Alzheimer's disease. Unlike tacrine, rivastigmine bitartrate has a stronger inhibitory effect on the G1 enzyme in the hippocampus and cortex. From the perspective of clinical application effects, because rivastigmine bitartrate has a high degree of brain area selectivity and dual inhibitory effects, it can significantly improve the self-care ability of patients with dementia, but donepezil has no improvement in this aspect; rivastigmine bitartrate is in The efficacy of social activity capacity is also better than donepezil. The "2018 China Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Impairment" pointed out that memantine combined with donepezil and rivastigmine can be used for the treatment of patients with moderate to severe AD with a clear diagnosis.

Hot Tags: rivastigmine bitartrate api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Fondaparinux API, Tetrabenazine API, Clofarabine API, Perindopril Arginine API, Ulipristal Acetate API, Lifitegrast API

• Previous: Tiapride API
• Next: Minodronic Acid API